Driehaus Capital Management LLC Boosts Stock Position in ADMA Biologics Inc $ADMA

Key Points

• Driehaus Capital Management LLC significantly increased its holdings in ADMA Biologics Inc by 114.9%, acquiring an additional 1,575,363 shares, totaling approximately 2.94 million shares valued at $58.46 million.
• Institutional investors own 75.68% of ADMA Biologics, with notable stake changes among various large investors during the first quarter of this year.
• ADMA Biologics reported a 13.8% increase in quarterly revenue year-over-year, achieving $121.98 million, alongside an EPS of $0.15, surpassing analysts’ expectations.

Driehaus Capital Management LLC boosted its position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 114.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,946,570 shares of the biotechnology company's stock after purchasing an additional 1,575,363 shares during the quarter. Driehaus Capital Management LLC owned approximately 1.24% of ADMA Biologics worth $58,460,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of ADMA. Envestnet Asset Management Inc. grew its stake in shares of ADMA Biologics by 68.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 60,004 shares of the biotechnology company's stock worth $1,029,000 after acquiring an additional 24,293 shares during the last quarter. Mariner LLC purchased a new stake in shares of ADMA Biologics in the fourth quarter worth $573,000. Hsbc Holdings PLC grew its stake in shares of ADMA Biologics by 38.0% in the fourth quarter. Hsbc Holdings PLC now owns 29,736 shares of the biotechnology company's stock worth $511,000 after acquiring an additional 8,186 shares during the last quarter. Northern Trust Corp grew its stake in shares of ADMA Biologics by 6.0% in the fourth quarter. Northern Trust Corp now owns 2,575,075 shares of the biotechnology company's stock worth $44,163,000 after acquiring an additional 145,387 shares during the last quarter. Finally, Freestone Grove Partners LP purchased a new stake in shares of ADMA Biologics in the fourth quarter worth $769,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 20,000 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the transaction, the director directly owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. This trade represents a 17.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the transaction, the director directly owned 478,194 shares in the company, valued at approximately $10,190,314.14. The trade was a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 455,621 shares of company stock valued at $9,461,633. Insiders own 3.70% of the company's stock.

ADMA Biologics Stock Performance

Shares of ADMA Biologics stock traded down $0.22 during trading on Wednesday, hitting $16.98. 2,045,331 shares of the company's stock traded hands, compared to its average volume of 3,106,951. The stock has a market capitalization of $4.05 billion, a P/E ratio of 19.76 and a beta of 0.54. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The business has a 50-day simple moving average of $17.74 and a 200-day simple moving average of $18.93. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.01. The business had revenue of $121.98 million for the quarter, compared to analysts' expectations of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The business's revenue for the quarter was up 13.8% on a year-over-year basis. During the same period last year, the firm posted $0.13 earnings per share. As a group, analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial increased their target price on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th. One research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $27.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.